Local Delivery and Glioblastoma: Why Not Combining Sustained Release and Targeting?

Glioblastoma is one of the most aggressive brain tumors and is associated with a very low overall median survival despite the current treatment. The standard of care used in clinic is the Stupp's protocol which consists of a maximal resection of the tumor when possible, followed by radio and ch...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Claire Gazaille, Marion Sicot, Patrick Saulnier, Joël Eyer, Guillaume Bastiat
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	glioblastoma Gliadel® wafers local delivery nanoparticle-loaded hydrogel targeting Medical technology R855-855.5
Acceso en línea:	https://doaj.org/article/19bdf9b402434c95a7a4c26116e2bb57
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:19bdf9b402434c95a7a4c26116e2bb57
record_format	dspace
spelling	oai:doaj.org-article:19bdf9b402434c95a7a4c26116e2bb572021-11-22T06:36:33ZLocal Delivery and Glioblastoma: Why Not Combining Sustained Release and Targeting?2673-312910.3389/fmedt.2021.791596https://doaj.org/article/19bdf9b402434c95a7a4c26116e2bb572021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fmedt.2021.791596/fullhttps://doaj.org/toc/2673-3129Glioblastoma is one of the most aggressive brain tumors and is associated with a very low overall median survival despite the current treatment. The standard of care used in clinic is the Stupp's protocol which consists of a maximal resection of the tumor when possible, followed by radio and chemotherapy using temozolomide. However, in most cases, glioblastoma cells infiltrate healthy tissues and lead to fatal recurrences. There are a lot of hurdles to overcome in the development of new therapeutic strategies such as tumor heterogeneity, cell infiltration, alkylating agent resistance, physiological barriers, etc., and few treatments are on the market today. One of them is particularly appealing because it is a local therapy, which does not bring additional invasiveness since tumor resection is included in the gold standard treatment. They are implants: the Gliadel® wafers, which are deposited post-surgery. Nevertheless, in addition to presenting important undesirable effects, it does not bring any major benefit in the therapy despite the strategy being particularly attractive. The purpose of this review is to provide an overview of recent advances in the development of innovative therapeutic strategies for glioblastoma using an implant-type approach. The combination of this local strategy with effective targeting of the tumor microenvironment as a whole, also developed in this review, may be of interest to alleviate some of the obstacles encountered in the treatment of glioblastoma.Claire GazailleMarion SicotPatrick SaulnierJoël EyerGuillaume BastiatFrontiers Media S.A.articleglioblastomaGliadel® waferslocal deliverynanoparticle-loaded hydrogeltargetingMedical technologyR855-855.5ENFrontiers in Medical Technology, Vol 3 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	glioblastoma Gliadel® wafers local delivery nanoparticle-loaded hydrogel targeting Medical technology R855-855.5
spellingShingle	glioblastoma Gliadel® wafers local delivery nanoparticle-loaded hydrogel targeting Medical technology R855-855.5 Claire Gazaille Marion Sicot Patrick Saulnier Joël Eyer Guillaume Bastiat Local Delivery and Glioblastoma: Why Not Combining Sustained Release and Targeting?
description	Glioblastoma is one of the most aggressive brain tumors and is associated with a very low overall median survival despite the current treatment. The standard of care used in clinic is the Stupp's protocol which consists of a maximal resection of the tumor when possible, followed by radio and chemotherapy using temozolomide. However, in most cases, glioblastoma cells infiltrate healthy tissues and lead to fatal recurrences. There are a lot of hurdles to overcome in the development of new therapeutic strategies such as tumor heterogeneity, cell infiltration, alkylating agent resistance, physiological barriers, etc., and few treatments are on the market today. One of them is particularly appealing because it is a local therapy, which does not bring additional invasiveness since tumor resection is included in the gold standard treatment. They are implants: the Gliadel® wafers, which are deposited post-surgery. Nevertheless, in addition to presenting important undesirable effects, it does not bring any major benefit in the therapy despite the strategy being particularly attractive. The purpose of this review is to provide an overview of recent advances in the development of innovative therapeutic strategies for glioblastoma using an implant-type approach. The combination of this local strategy with effective targeting of the tumor microenvironment as a whole, also developed in this review, may be of interest to alleviate some of the obstacles encountered in the treatment of glioblastoma.
format	article
author	Claire Gazaille Marion Sicot Patrick Saulnier Joël Eyer Guillaume Bastiat
author_facet	Claire Gazaille Marion Sicot Patrick Saulnier Joël Eyer Guillaume Bastiat
author_sort	Claire Gazaille
title	Local Delivery and Glioblastoma: Why Not Combining Sustained Release and Targeting?
title_short	Local Delivery and Glioblastoma: Why Not Combining Sustained Release and Targeting?
title_full	Local Delivery and Glioblastoma: Why Not Combining Sustained Release and Targeting?
title_fullStr	Local Delivery and Glioblastoma: Why Not Combining Sustained Release and Targeting?
title_full_unstemmed	Local Delivery and Glioblastoma: Why Not Combining Sustained Release and Targeting?
title_sort	local delivery and glioblastoma: why not combining sustained release and targeting?
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/19bdf9b402434c95a7a4c26116e2bb57
work_keys_str_mv	AT clairegazaille localdeliveryandglioblastomawhynotcombiningsustainedreleaseandtargeting AT marionsicot localdeliveryandglioblastomawhynotcombiningsustainedreleaseandtargeting AT patricksaulnier localdeliveryandglioblastomawhynotcombiningsustainedreleaseandtargeting AT joeleyer localdeliveryandglioblastomawhynotcombiningsustainedreleaseandtargeting AT guillaumebastiat localdeliveryandglioblastomawhynotcombiningsustainedreleaseandtargeting
_version_	1718418087904018432

Local Delivery and Glioblastoma: Why Not Combining Sustained Release and Targeting?

Ejemplares similares